Nika Pharmaceuticals, Inc. reported a net loss of $76,398 for the fiscal year ending December 31, 2025, a decrease from the net loss of $95,792 recorded in the previous year. The company's total operating expenses for 2025 were $76,398, which included general and administrative expenses of $53,026, reflecting a 50.75% increase from $35,174 in 2024. Professional fees, however, saw a significant reduction, dropping by 61.44% to $23,372 from $60,618 in the prior year. The company’s accumulated deficit increased to $9,004,009 as of December 31, 2025, compared to $8,927,612 at the end of 2024.
In terms of strategic developments, Nika Pharmaceuticals has undergone significant changes, including a merger with Nika BioTechnology, Inc. on February 12, 2024. This merger resulted in Nika Pharmaceuticals acquiring an 80% controlling interest in Nika Europe, Ltd., which is preparing to construct a pharmaceutical factory. The company also signed several exclusive rights agreements for the production and distribution of various products, including Thymus Nuclear Glycoprotein and dietary supplements. These agreements are expected to enhance the company’s product offerings and market presence.
Operationally, Nika Pharmaceuticals has not reported any revenue generation to date, and its cash position decreased slightly to $1,889 at the end of 2025 from $2,083 in 2024. The company’s total liabilities increased to $318,624, up from $239,164 in the previous year, primarily due to advances from related parties. The company’s employee headcount remains low, with only two executive officers managing operations. The company has not yet established formal insider trading policies, reflecting its early-stage development.
Looking ahead, Nika Pharmaceuticals acknowledges the need for additional financing to sustain operations and achieve profitability. Management has indicated plans to seek further equity or debt financing, although there is no assurance that such funding will be available on acceptable terms. The company’s ability to continue as a going concern is contingent upon its success in raising capital and ultimately generating revenue from its product lines. The independent auditors have expressed substantial doubt regarding the company's ability to continue operations without additional funding.
About NIKA PHARMACEUTICALS, INC
Nika Pharmaceuticals Inc. develops and commercializes pharmaceutical and dietary supplement products, focusing on innovative treatments and health solutions. The company holds exclusive rights, engages in strategic mergers, and operates in global markets including Europe, Asia, and Africa. It invests in manufacturing facilities, technology acquisitions, and product development, aiming to provide healthcare solutions through partnerships, licensing, and proprietary technologies within the biotech and pharma sectors.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.